[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Health Agencies Update
April 24, 2013

Diabetes Drugs Investigated

JAMA. 2013;309(16):1674. doi:10.1001/jama.2013.4243

The US Food and Drug Administration (FDA) is investigating unpublished data suggesting that incretin mimetics used to treat type 2 diabetes may increase the risk of pancreatitis or precancerous changes in the pancreas (http://tinyurl.com/437wln9).

According to the FDA, a team of academic researchers examined pancreatic tissue samples from patients who died of unspecified causes. The data prompted the agency to begin its own investigation of potential pancreatic toxicity associated with this class of drugs, which includes exenatide, liraglutide, sitagliptin, saxagliptin, alogliptin, and linagliptin. The agency emphasized that it has not yet reached a conclusion.